The nature of immune dysregulation is markedly different between various MDS risk groups. In low-risk MDS, the immune system is in a proinflammatory state, whereas in high-risk disease ...

Rytelo is approved for low-risk MDS patients with transfusion-dependent anemia, excluding those with isolated deletion 5q. Phase 3 IMerge trial data demonstrated significant reduction in red blood ...

If approved, it would compete with Bristol-Myers Squibb’s erythroid maturation agent Reblozyl (luspatercept), which was cleared to treat anaemia in adults with low-risk, relapsed MDS in 2020 and ...

low or intermediate risk myelodysplastic syndromes (lower-risk MDS or LR-MDS) without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ...

MDS are a group of closely related blood cancers ... However, frequent transfusions are associated with an increased risk of iron overload, transfusion reactions, and infections in themselves.

Caspian Oliai, MD, MS, medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center, discusses findings from the phase 3 Precision-T trial of Orca-T in acute leukemia and ...